Leung, Nina PhD, MPH; Bernacki, Seth E. BA; Bernacki, Edward J. MD, MPH
Author Information
Dell Medical School, The University of Texas at Austin, Austin, Texas; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland (Dr Leung and Dr Bernacki); University of the Incarnate Word School of Osteopathic Medicine, San Antonio, Texas (Mr Bernacki).
Address correspondence to: Nina Leung, PhD, MPH, Dell Medical School, The University of Texas at Austin, 1601 Trinity Street, Stop Z0200, Austin, TX 78712-1850 ([email protected]).
The authors report no conflicts of interest.
Clinical Significance: The declining incidence of acute HCV infections and the introduction of efficacious HCV treatment options for chronic HCV in this commercial population have resulted in significant reductions in HCV-related medical claims and the clinical sequelae of advanced liver diseases. Although HCV treatment to achieve sustained viral response (SVR) remains expensive, the prevention of advanced liver disease decreased system-wide medical costs for this insured population.
Supplemental digital contents are available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.joem.org).
doi: 10.1097/JOM.0000000000001633
